ICU Medical (ICUI) Q2 EPS Jumps 40%

Key Points

• ICU Medical (NASDAQ:ICUI) reported Non-GAAP EPS of $2.10, beating analyst expectations by 40.0% (non-GAAP).

• Revenue came in at $543.6 million (Non-GAAP)

• Guidance for FY2025 was narrowed, with management signaling caution around tariffs, regulatory costs, and Vital Care segment performance.

• These 10 stocks could mint the next wave of millionaires ›

ICU Medical (NASDAQ:ICUI), a medical device company specializing in infusion therapy and related products, released its second quarter results on August 7, 2025. The most important news from the report was a significant earnings per share (EPS) beat, with adjusted EPS of $2.10 (Non-GAAP) compared to analyst expectations of $1.50, a positive difference of 40.0% (Non-GAAP). Despite outperforming consensus numbers, GAAP revenue saw continued contraction and company guidance narrowed for FY2025, reflecting ongoing caution tied to regulatory challenges, tariffs, and shrinking sales in some segments.

Source: Analyst estimates for the quarter provided by FactSet.

Business Overview and Focus Areas

The company develops, manufactures, and sells devices used to deliver medications and fluids to hospital patients. Its product range includes infusion pumps—electronic devices that control the rate at which fluids are delivered—IV sets and consumables, and hospital software systems for drug delivery safety. Infusion pumps are especially important in critical care settings, ensuring precise control of drug administration.

In recent years, the business has concentrated heavily on three priorities: expanding and refreshing its product portfolio through new launches and past acquisitions, managing compliance with complex healthcare regulations, and navigating global supply chain risks. Success for the company depends on continued product innovation, smooth regulatory approvals, and managing manufacturing costs amid shifting tariffs and competitive pressures.

Quarter in Review: Revenue, Margins, and Portfolio Shifts

The period marked a beat on both top and bottom lines relative to Wall Street forecasts, with revenue (GAAP) and EPS (non-GAAP) both exceeding analyst estimates. Adjusted EPS surged to $2.10, well above the $1.50 expected by analysts. Adjusted EBITDA climbed 9.8%, helped by strict cost controls and a shift towards higher-margin products. Gross margin rose by three percentage points to 38% (GAAP).

Mainly due to a significant fall in the Vital Care segment. This part of the business dropped sharply, reflecting the effect of creating a joint venture for IV Solutions as well as ongoing soft demand and reduced contract manufacturing activity. Contract manufacturing in Vital Care was down from $15.5 million to $5.3 million year over year.

In contrast, the Consumables segment (which includes disposable IV sets and safety products) posted solid growth, benefiting from market gains in oncology, renal care, and home infusion therapy. The Infusion Systems segment (home to the company’s line of infusion pumps and related LifeShield safety software) also rose slightly by 2.4% year-over-year, but new pump launches like PlumDuo and PlumSolo are only just starting to make an impact. Management notes these new products have received critical regulatory clearance. The majority of their revenue lift from hospital upgrades and replacements is expected to happen late 2025 and into future periods, given the typical upgrade cycles for hospital equipment.

Operationally, the company continued aggressive investment in pump innovation, but regulatory hurdles persisted. The business remains under U.S. Food and Drug Administration (FDA) supervision due to legacy compliance matters inherited from its acquisition of Smiths Medical. While nearly all MedFusion infusion pumps in the field have been remediated following recent recalls, new 510(k) product filings have been mandated by the FDA and are underway. Clearance timing for these products is uncertain, though management expects filings to be completed within about ninety days of the previous update. Resolution is key, since regulatory actions can affect both product sales and ongoing remediation expenses, which have been one of the largest cash outlays over the past two years.

Tariff-related costs stand out as another headwind. Management estimates up to $30 million of tariff exposure in FY2025, mainly due to new trade measures targeting imports from Costa Rica, China, and some non-USMCA-compliant products from Mexico. While about half of this burden may be offset by currency effects and company cost measures, the remaining $5–$10 million could still affect margins and profitability. Efforts such as dual sourcing, vendor changes, and selective price increases are underway, but some tariff costs may persist until these new supply chain setups are implemented.

Despite strong profit growth, free cash flow (non-GAAP) was negative at $(8.5) million, down steeply from $62.7 million positive in free cash flow for Q2 2024. The company did, however, use proceeds from recent asset sales and joint ventures to pay down $247.8 million in long-term debt, leaving it with $1.34 billion in debt and $300 million in cash.

Looking Forward: Guidance and Key Themes

For FY2025, management updated its full-year outlook, including both GAAP and non-GAAP (adjusted) guidance. The projected adjusted (non-GAAP) diluted EPS range for FY2025 was tightened slightly to $6.85–$7.15, raising the floor and bringing in the top. Adjusted EBITDA guidance is now $380–$390 million for FY2025, a reduction at the high end from the previous $405 million in adjusted EBITDA guidance. The move reflects caution around persistent tariff costs, unpredictable regulatory timelines, and the risk of continued weakness in the Vital Care segment. The company stated that its goal is to deliver at least at the lower end of this narrowed range for both adjusted EPS and profits. Management emphasized that while some factors such as foreign currency are helping to offset tariffs, further unexpected developments could affect results as the year progresses.

Investors should continue to monitor several key areas in upcoming quarters: the pace at which new infusion pumps are adopted and begin to produce meaningful revenue, progress in resolving all outstanding FDA regulatory issues, and any further developments on tariffs and raw materials. The business has not declared a dividend—so capital return is solely through debt paydown and reinvestment in operations. ICUI does not currently pay a dividend.

Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,046%* — a market-crushing outperformance compared to 181% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of August 4, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.